---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-006711"
form_type: "8-K"
ticker: null
cik: "0001061027"
company_name: "Viracta Therapeutics, Inc."
filed_at: "2025-01-17T23:59:59+00:00"
generated_at: "2026-05-27T22:55:29.926834+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viracta receives Nasdaq notice for audit committee non-compliance; cure period through Dec 2025

## Summary
- Nasdaq notice dated Jan 13, 2025 for failing audit committee requirement under Rule 5605(c)(2).
- Non-compliance triggered by resignation of board member Barry J. Simon, M.D. on Dec 18, 2024.
- Cure period runs until the earlier of next annual meeting or Dec 18, 2025.
- If annual meeting before June 16, 2025, compliance evidence due by June 16, 2025.

## SEC filing metadata
- accession: 0000950170-25-006711
- form_type: 8-K
- cik: 0001061027
- company_name: Viracta Therapeutics, Inc.
- filed_at: 2025-01-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017025006711/0000950170-25-006711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017025006711/virx-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-006711
- JSON: https://secwatch.observer/filing/0000950170-25-006711.json
- Plain text: https://secwatch.observer/filing/0000950170-25-006711.txt

## Source-grounded claims
- claim_id: 0effc43c914e72673db7cc038876a8e9ec934403
  claim: Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).
  evidence_excerpt: January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017025006711/0000950170-25-006711-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.